We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
